logo
logo

Isofol Raises Sek 500 Million In Oversubscribed Rights Issue And Exercised Over-Allotment Option

Isofol Raises Sek 500 Million In Oversubscribed Rights Issue And Exercised Over-Allotment Option

06/14/21, 8:47 AM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/SE.svggothenburg
Isofol Medical AB (publ) (Nasdaq First North Premier Growth Market: ISOFOL) ("Isofol" or the "Company") fully guaranteed new share issue with preferential rights for the Company's existing shareholders (the "Rights Issue"), which ended on June 10, 2021, was oversubscribed. Due to the strong demand from strategic investors, a directed issue with deviation from the shareholders' preferential rights of approximately SEK 100 million (the "Over-Allotment Option") was exercised. Through the Rights Issue and the Over-Allotment Option, Isofol will receive proceeds amounting to approximately SEK 500 million before transaction costs.

Company Info

Company
Isofol Medical Ab (Publ)
Location
gothenburg, västra götalands län, sweden
Additional Info
Isofol Medical AB (publ) is a clinical stage biotech company developing arfolitixorin to improve the efficacy of standard of care chemotherapy for advanced colorectal cancer by increasing tumor response and progression free survival. Isofol holds a worldwide exclusive license agreement with Merck KGaA, Darmstadt, Germany to develop and commercialize arfolitixorin for oncology indications. Isofol Medical AB (publ) is traded on the Nasdaq First North Premier Growth Market. Certified Adviser is FNCA Sweden AB.